Pfizer Reports $16.6B Q3 Revenue with 32% Growth in Launched Products
Pfizer's Q3 results show strong growth driven by key medicines, despite declines in COVID-19 product sales.
Pfizer's Q3 results show strong growth driven by key medicines, despite declines in COVID-19 product sales. This is an original TLT brief synthesising 2 outlets (Blockonomi, The Coin Republic), plus live market data, as of Tue, 03 Nov 2026 22:00:04 UTC.
Pfizer's performance highlights the shifting dynamics in pharmaceutical revenue as COVID-19 product sales decline while other medicines drive growth, impacting future revenue guidance and market positioning.
- Pfizer's Q3 revenue reached $16.6 billion with 32% growth in launched products.
- Eliquis, Padcev, and Lorbrena are key growth drivers amid declines in Paxlovid and Comirnaty sales.
- Pfizer raises 2026 revenue guidance to $62-$64 billion.
- Total market cap at $2.68T with Bitcoin up 1.36% in 24 hours.
Blockonomi and The Coin Republic both report Pfizer's Q3 revenue of $16.6 billion and 32% growth in launched products, with Eliquis, Padcev, and Lorbrena as key contributors. They also agree on the decline in Paxlovid (63%) and Comirnaty (29%) sales. However, The Coin Republic provides additional details on the company's amended IPO filing, revealing a $23.29 billion quarterly net loss and $895.4 billion in commitments, which Blockonomi does not mention.
Pfizer has reported a Q3 revenue of $16.6 billion, with launched products contributing to a 32% growth compared to the same period last year. This performance is primarily driven by the strong sales of medicines such as Eliquis, Padcev, and Lorbrena, as detailed by multiple outlets.
Despite the overall growth, the company experienced significant declines in sales of its COVID-19 products. Paxlovid revenue dropped by 63%, and Comirnaty sales decreased by 29% during the quarter. These declines reflect the changing landscape of the pharmaceutical market as the demand for COVID-19 treatments wanes.
Pfizer has responded to its strong performance by raising its 2026 revenue guidance to a range of $62 billion to $64 billion. This adjustment underscores the company's confidence in its product portfolio and growth strategy moving forward.
The broader market context shows a total crypto market cap of $2.68 trillion, with 
Bitcoin experiencing a 1.36% increase in the past 24 hours. While Pfizer's performance is not directly linked to crypto markets, it reflects the broader economic conditions that can influence investor sentiment across different asset classes.
The company's ability to adapt to changing market conditions and its strategic focus on expanding its medicine portfolio will be crucial in maintaining its growth trajectory. Investors and analysts will be watching closely to see how Pfizer navigates the post-pandemic landscape and continues to drive innovation in the pharmaceutical industry.
Pfizer Reports $16.6B Q3 Revenue with 32% Growth in Launched — questions & answers
What were the key growth drivers for Pfizer in Q3?
Eliquis, Padcev, and Lorbrena were the key growth drivers for Pfizer in Q3.
How much did Paxlovid and Comirnaty sales decline in Q3?
Paxlovid revenue dropped by 63%, and Comirnaty sales decreased by 29%.
What is Pfizer's updated 2026 revenue guidance?
Pfizer's updated 2026 revenue guidance is $62 billion to $64 billion.
Which outlets reported this story?
This is an original TLT brief that synthesises reporting from Blockonomi, The Coin Republic, with the key figures cross-checked for agreement across them. It is not a copy of any one article — follow the source links above for the original reporting.
Original summary — not financial advice. This is an original TLT brief that summarises a development reported elsewhere and adds live market data for context; it is not the original article and reproduces no part of it. Follow the source link above for full details. Crypto is volatile and high-risk — always do your own research.